Top 5 small and mid-cap performers of FY19
Top 5 small and mid-cap performers of FY19

Top 5 small and mid-cap performers of FY19

Nidhi Jani Article rating: 5.0

In the fiscal year 2018-19, the Indian Stock market went through a roller coaster ride due to various reasons such as geopolitical tension, trade war, liquidity crisis caused by IL&FS default, rising crude oil prices and weakening of INR.

Cholamandalam Investment reports healthy asset quality
Cholamandalam Investment reports healthy asset quality

Cholamandalam Investment reports healthy asset quality

Amir Shaikh Article rating: 5.0

The company's GNPA and NNPA in Q4FY19 reduced to 2.3 per cent and 1.1 per cent from 3 per cent and 1.7 per cent in Q4FY18, respectively. The provision coverage ratio for the quarter was at 49.8 per cent as against 44.2 per cent in Q4FY18. 

Overnight Digest: Stocks to watch out on April 30
Overnight Digest: Stocks to watch out on April 30

Overnight Digest: Stocks to watch out on April 30

Shohini Nath Article rating: 3.0

The stocks that are likely to witness significant movement on the bourses on April 30 are SBI Life Insurance Company, Tata Global Beverages, Piramal Enterprises, KPR Mill and HDFC AMC. 

Should retail investors invest in NCDs?
Should retail investors invest in NCDs?

Should retail investors invest in NCDs?

Gayathri Udyawar Article rating: 4.0

Most retail investors want returns of a bull market but with the safety similar to that of bank fixed deposits (FDs). The present low interest environment is making bank deposits less attractive. Let's us find out whether corporate NCDs would be an ideal choice for risk averse investors.

How to use price multiple ratios to evaluate stocks?
How to use price multiple ratios to evaluate stocks?

How to use price multiple ratios to evaluate stocks?

Nidhi Jani Article rating: 4.2

For stock valuation, we use various price multiples like P/E, P/B and P/S. These ratios are quite interesting and knowing which price multiple to use when is very important.

Dr. Reddys recalls Divalproex tablets
Dr. Reddys recalls Divalproex tablets

Dr. Reddys recalls Divalproex tablets

Amir Shaikh Article rating: 4.0

Dr Reddy's Laboratories has reportedly initiated a voluntary recall of anti-seizure drug Divalproex extended-release tablets from the US market owing to cGMP deviations noticed in certain batches of the product.

RSS
First25972598259926002602260426052606Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR